SARS-CoV-2 (COVID-19) NSP16 Antibody | 20-276

SARS-CoV-2 (COVID-19) NSP16 Antibody | 20-276 | Gentaur UK, US & Europe Distribution

Host: Sheep

Reactivity: Virus

Homology: N/A

Immunogen: GST-SARS-CoV2 NSP16

Research Area: Infectious Disease, COVID-19

Tested Application: WB

Application: Detection Antibodies: 1 μg/ml Ab, 5% BSA in TBS-T, 4˚C overnight
Blocking: 5% milk in TBS-T, 1h room temp
Secondary Antibodies: 1:15, 000 donkey anti-sheep, 1:15, 000 donkey anti-rabbot, in TBS-T, 1h room temp
Wash: TBS-T, 4x 10 min

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Antibodies are affinity purified against the antigen and eluted with low pH.

Clonality: Polyclonal

Clone: N/A

Isotype: N/A

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Antibody supplied in PBS.

Concentration: batch dependent

Storage Condition: Aliquot and store at -20˚C. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: SARS-CoV-2-NSP16

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro) , are attractive antiviral drug targets because they are essential for coronaviral replication. PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells.